Dr. Edwige Voisset completed her PhD at the Marseille Cancer Research Centre (CRCM) under the supervision of Paulo de Sepulveda in Patrice Dubreuil’s research group, focusing on the role of FES and FER kinases in both physiological and leukaemic signalling pathways downstream of the KIT and FLT3 tyrosine kinase receptors. Afterward, she moved to Cambridge for her first postdoctoral position, crossing the English Channel to join the MRC Cambridge Stem Cell Institute. There, she spent three years investigating the impact of p38alpha on the transformation potential of KRas-mutated bronchioalveolar stem cells. Following this valuable experience in oncology research, Edwige returned to the leukaemia field for her second postdoc, joining the late David Grimwade’s research group at King’s College London (KCL). Her work there centered on exploring the role of PML nuclear body disruption in the initiation and progression of acute promyelocytic leukaemia (APL). In 2019, she was awarded a Marie Skłodowska-Curie Fellowship (MSCA) by H2020, enabling her to return to the CRCM in Paulo de Sepulveda’s group, where she launched her own research project investigating the involvement of NPM1 and its mutants in DNA damage repair.
In September 2024, Edwige joined Vladimir Torbeev’s research group at the Strasbourg School of Engineering in Biotechnology (ESBS) – UMR 7242. In this pluridisciplinary environment, she continues her research on NPM1 biology, leveraging the team’s expertise in chemistry to advance her work.
Publications:
Desaunay M, Voisset E, Letard S, Roche P, De Sepulveda P. – The recurrent liver MAN2A1-FER oncoprotein lacks kinase activity: Implications for the use of tyrosine kinase inhibitors. – Cell Mol Gastroenterol Hepatol. 2024;17(4):667-669.
Saez-Ayala M, Hoffer L, Abel S, Ben Yaala K, Sicard B, Andrieu GP, Latiri M, Davison EK, Ciufolini MA, Brémond P, Rebuffet E, Roche P, Derviaux C, Voisset E, Montersino C, Castellano R, Collette Y, Asnafi V, Betzi S, Dubreuil P, Combes S and Morelli X. – Drug repositioning to drug design strategy, tackling lymphoblastic leukemia as a proof of concept. – Nat Comm. 2023 May 29;14(1):3079.
Rigo R, Chelbi R, Agopian J, Letard S, Griffon A, Ghamlouch H, Vernerey J, Ladopoulos V, Voisset E, De Sepulveda P, Guittard G, Nunès JA, Bidaut G, Göttgens B, Weber M, Bernard OA, Dubreuil P, Soucie E. – Tet2 regulates immune tolerance in chronically activated mast cells – JCI Insight. 2022 Apr 8;7(7):e154191
Voisset E, Brenet F, Lopez S, de Sepulveda P. – SRC-Family Kinases in Acute Myeloid Leukaemia and Mastocytosis. – Cancers (Basel). 2020 Jul 21;12(7):1996.
Ozgencil M, Barwell J, Tischkowitz M, Izatt L, Kesterton I, Simpson M, Sharpe P, de Sepulveda P, Voisset E, Solomon E. – Assessing BRCA1 activity in DNA damage repair using human induced pluripotent stem cells as an approach to assist classification of BRCA1 variants of uncertain significance. – PLoS One. 2021 Dec 2;16(12):e0260852.
Voisset E, Moravcsik E, Stratford EW, Jaye A, Palgrave C, Hills R, Salomoni P, Kogan SC, Solomon E, Grimwade D. – Pml nuclear body disruption impairs crosstalk between DNA damage repair factors contributing to APL pathogenesis in mice. – Blood. 2018 Feb 8;131(6):636-648.
Grey W, Ivey A, Milne TA, Haferlach T, Grimwade D, Uhlmann F, Voisset E, Yu V. – The Cks1/Cks2 axis fine-tunes Mll1 expression and is crucial for MLL-rearranged leukaemia cell viability. – BBA-Mol Cell Res. 2018 Jan;1865(1):105-116.
Jovanovic JV, Chillón MC, Vincent-Fabert C, Dillon R, Voisset E, Gutiérrez NC, Sanz RG, Lopez AA, Morgan YG, Lok J, Solomon E, Duprez E, Díaz MG, Grimwade D. – The cryptic IRF2BP2-RARA fusion transforms hematopoietic stem/progenitor cells and induces retinoid-sensitive acute promyelocytic leukemia. – Leukemia. 2017 Mar;31(3):747-751.
Voisset E, Oeztuerk-Winder F, Ruiz EJ, Ventura JJ. – p38α negatively regulates survival and malignant selection of transformed bronchioalveolar stem cells. – PLoS One. 2013 Nov 12;8(11):e78911.
Lopez S, Voisset E, Tisserand JC, Mosca C, Prebet T, Santamaria D, Dubreuil P, De Sepulveda P. – An essential pathway links FLT3-ITD, HCK and CDK6 in acute myeloid leukemia. – Oncotarget. 2016 Aug 9;7(32):51163-51173.
Chaix A, Arcangeli ML, Lopez S, Voisset E, Yang Y, Vita M, Letard S, Audebert S, Finetti P, Birnbaum D, Bertucci F, Aurrand-Lions M, Dubreuil P, De Sepulveda P. – KIT-D816V oncogenic activity is controlled by the juxtamembrane docking site Y568-Y570. – Oncogene. 2014 Feb 13;33(7):872-81.
Chaix A, Lopez S, Voisset E, Gros L, Dubreuil P, De Sepulveda P. – Mechanisms of STAT proteins activation by oncogenic kit mutants in neoplastic mast cells. – J Biol Chem. 2011 Feb 25;286(8):5956-66.
Voisset E, Lopez S, Chaix A, Vita M, George C, Dubreuil P, De Sepulveda P. – FES kinase participates in KIT-ligand induced chemotaxis. – Biochem Biophys Res Commun. 2010 Feb 26;393(1):174-8.
Voisset E, Lopez S, Chaix A, Georges C, Hanssens K, Prébet T, Dubreuil P, De Sepulveda P. – FES kinases are required for oncogenic FLT3 signaling. – Leukemia. 2010 Apr;24(4):721-8.
Dubreuil P, Letard S, Ciufolini M, Gros L, Humbert M, Castéran N, Borge L, Hajem B, Lermet A, Sippl W, Voisset E, Arock M, Auclair C, Leventhal PS, Mansfield CD, Moussy A, Hermine O. – Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. – PLoS One. 2009 Sep 30;4(9):e7258.
Voisset E, Lopez S, Dubreuil P, De Sepulveda P. – The tyrosine kinase FES is an essential effector of KITD816V proliferation signal – Blood. 2007 Oct 1;110(7):2593-9.